buformin and Sepsis
buformin has been researched along with Sepsis in 1 studies
Buformin: An oral hypoglycemic agent that inhibits gluconeogenesis, increases glycolysis, and decreases glucose oxidation.
buformin : A member of the class of biguanides that is biguanide substituted by a butyl group at position 1. It is an antidiabetic drug with potential antitumor effect.
Sepsis: Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Liu, B | 1 |
| Wang, Z | 1 |
| He, R | 1 |
| Xiong, R | 1 |
| Li, G | 1 |
| Zhang, L | 1 |
| Fu, T | 1 |
| Li, C | 1 |
| Li, N | 1 |
| Geng, Q | 1 |
Other Studies
1 other study available for buformin and Sepsis
| Article | Year |
|---|---|
Buformin alleviates sepsis-induced acute lung injury via inhibiting NLRP3-mediated pyroptosis through an AMPK-dependent pathway.
Topics: Acute Lung Injury; AMP-Activated Protein Kinases; Animals; Autophagy; Buformin; Cell Line; Drug Eval | 2022 |